Personalized pills may rescue sleep apnea patients failed by standard devices

NCT ID NCT05293600

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether adding a drug tailored to a person's specific sleep apnea subtype can help when a mouthpiece or tongue nerve stimulator still leaves them with breathing pauses. Participants whose device did not fully control their apnea will receive either a placebo or one of three drugs—acetazolamide, trazodone, or atomoxetine-plus-eszopiclone—chosen based on their individual sleep apnea cause. The goal is to see if the drug can further reduce the number of breathing interruptions during sleep.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
acetazolamide, trazodone, or atomoxetine-plus-eszopiclone depending on the person's sleep apnea subtype
What this could lead to
If successful, this could offer a drug-based rescue option for people whose mouthpiece or nerve stimulator does not fully control their sleep apnea.
What could go wrong
This is an early-phase trial with only 70 participants, so results may not apply to everyone. The drugs also have side effects and may not work for all subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sleep Disorders Research Program Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.